Oragenics gets NYSE American extension to February 2028 to regain listing compliance
OGEN•NYSE Regulation accepted Oragenics’ compliance plan on Nov. 11, 2026, giving the company until Feb. 25, 2028, to meet listing standards. Its shares will remain listed during the period, subject to plan milestones and ongoing reviews.
1. Compliance extension
NYSE Regulation accepted Oragenics’ compliance plan on Nov. 11, 2026, granting the company until Feb. 25, 2028, to regain compliance with listing standards. Oragenics shares will remain listed on NYSE American during the period, subject to plan milestones and ongoing reviews.
2. Deficiency details
An Aug. 26, 2026, deficiency notice cited stockholders’ equity of $3.7 million as of June 30, 2026. Noncompliance also reflected losses from continuing operations and/or net losses in the five fiscal years ended Dec. 31, 2025.
